Editor: Zareen Amtul

Frontiers in Clinical Drug Research - CNS and Neurological Disorders

Volume 11

eBook: US $89 Special Offer (PDF + Printed Copy): US $153
Printed Copy: US $108
Library License: US $356
ISSN: 2451-8883 (Print)
ISSN: 2214-7527 (Online)
ISBN: 978-981-5123-32-6 (Print)
ISBN: 978-981-5123-31-9 (Online)
Year of Publication: 2023
DOI: 10.2174/97898151233191231101


Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology.

The eleventh volume of this series features reviews that cover the following topics related to the treatment of a variety of CNS disorders, related diseases, and basic research:

- The Multi-target Directed Ligands candidate (MTDLs) prototypes for neurodegenerative diseases

- Drugs for relapse prevention in addiction

- Neuroprotective activities of cinnamic acids and their derivatives in neurodegenerative disorders

- Phytosome for targeted delivery of natural compounds in treating alzheimer's disease

- Physical activity as a non-pharmacologic method for treatment of alzheimer’s disease


Pharmaceutical scientists, clinical researchers, medical consultants and allied healthcare professionals interested in neuropharmacology and neurology.


Studying brain physiology and development is a leading neuroscience strategy not only to illuminate the general understanding of brain structure and function but also to make progress against neurodegenerative disorders that are devastating the healthy aging.

The volume 11 of our book series Frontiers in Clinical Drug Research - CNS and Neurological Disorders introduces the subject of neurodegeneration by outlining the pathophysiology genetics, and environmental factors. This book besides providing a clear overview of the neurodegeneration and addiction process also introduces the readers to a new synthesis of ideas. To contextualize the research for the general readers, it also provides a brief introduction to the pharmacological and non-pharmacological approaches to treat the commonest neurodegenerative and addictive disorders. This book takes interested beginners on a journey from a cold start to a grasp of neuroscience’s best line of research. The current volume integrates the work of neurobiologists into a coherent account of the nature of neurodegenerative and addictive disorders and their treatment.

For instance, Chapter 1 highlights the multi-target directed ligands candidate prototypes inspired mostly by natural products to treat some of the most studied diseases, namely, Parkinson’s Disease, Alzheimer’s Disease, and Huntington’s Disease, as well as amyotrophic lateral sclerosis. Chapter 2 discusses the role of psychological and neurological factors as well as genetics and neurobiological mechanisms to review the drugs used for relapse prevention to treat addiction to nicotine, alcohol, or illicit drugs. Chapter 3 summarizes the neuroprotective properties of cinnamic acids and their derivatives in light of their mechanistic aspects to treat various neurodegenerative disorders. Chapter 4 reviews the role of phytosome in the targeted delivery of natural compounds across the blood brain-barrier to improve the efficacy, and bioavailability of Alzheimer's drugs. Chapter 5 glances at clinical trials investigating non-pharmacologic approaches, such as physical activity to improve the symptoms of Alzheimer’s Disease.

Briefly, this volume is the definitive guide to common neurodegenerative diseases that affect humans. The book covers the mechanisms of some of the most well-known neurodegenerative and addictive diseases, their biomarkers, neuropharmacology, and emerging treatment strategies.

We are grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications), and Ms. Asma Ahmed (Senior Manager Publications) at Bentham Science Publishers.

Zareen Amtul
The University of Windsor
Department of Chemistry and Biochemistry
Windsor, ON


.Frontiers in Clinical Drug Research - CNS and Neurological Disorders.
.Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches.
.Frontiers in Clinical Drug Research - CNS and Neurological Disorders.